Skip to main content

Table 1 Relevant data extraction information

From: Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review

Data extraction category Specific information to extract
A. Model characteristics
Model Author(s), year of publication, model design (static model, dynamic model, or hybrid model)
Perspective Providers, patients, or societal perspective
Benefits (QALY, DALY, YLS) Measured in quality-adjusted life years (QALYs), disability-adjusted life years (DALY), years of life saved (YLS)
B. Base-case assumptions
Current routine practice efficacy Efficacy of the current screening practice (cytology-based screening, DNA screening, or visual inspection with acetic acid) used as the comparator
Screening age/screening interval Age at which women commence screening and screening interval
Vaccine coverage in target groups Current HPV vaccination coverage
Age for vaccination Age group eligible to receive HPV vaccination
Estimated effective coverage HPV vaccination coverage and the rationale for the assumption
Screening compliance Estimate used for comparison with current practice
Sensitivity/specificity of the screening Sensitivity/specificity estimate for the screening methods
Duration of vaccine protection Total length of time HPV vaccination is assumed to protect the recipient from acquiring infection
Cost of vaccine per three doses (and booster if included) Market cost or subsidized cost. Other cost associated with vaccination, e.g., freight, storage, and program cost. School-based-delivery cost or health-facility-based delivery cost
Discounting rate Discounting rate used to adjust for time preference for money
C. Results
Incremental cost-effectiveness ratio (ICER) The most cost-effective protocol compared with the second best protocol
Year based for currency value The year which the analysis was conducted
Adjusted ICER (to 2014) Adjusted ICER to reflect 2014 value
Data sources
Source(s) Data source used to derive estimates of HPV-related epidemiologic outcomes, e.g., HPV (type-specific) prevalence, cervical cancer incidence, probability of HPV transmission given a sexual partnership, and crude mortality from cervical cancer.
D. Sensitivity and uncertainty
Sensitivity analysis Parameters that had the highest effect on model-based recommendation.
Uncertainty analysis The contribution of individual parameters on overall uncertainty (when reported).
E. Miscellaneous
Funding and conflict of interest Funding for the study and the role of the funder in the study. Possible conflict of interest declared by the author
Factors not taken into account How did model acknowledge and account for special challenges of the LMIC? Choice of modelling herd immunity